In this collaborative research, Shionogi aims to create new peptide drug conjugates by linking drugs or drug candidate compounds to cargo peptides which are able to pass the blood-brain-barrier.
Shionogi news release, January 23, 2019
Shionogi to cooperate with PeptiDream Co. on peptide drug conjugates which pass blood-brain-barrier